Oligodendrocyte Precursor Cell Therapy

📖 Wiki Page

therapeutic752 wordssynced 2026-04-02

Oligodendrocyte Precursor Cell Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Oligodendrocyte Precursor Cell Therapy</th>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Source</td>
</tr>
<tr>
<td class="label">Human OPCs</td>
<td>Fetal brain tissue</td>
</tr>
<tr>
<td class="label">iPSC-derived OPCs</td>
<td>Patient iPSCs</td>
</tr>
<tr>
<td class="label">MSC-derived OPCs</td>
<td>Bone marrow</td>
</tr>
<tr>
<td class="label">NG2 glia</td>
<td>Adult CNS</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Cell Type</td>
</tr>
<tr>
<td class="label">NCT03269071</td>
<td>Autologous MSCs</td>
</tr>
<tr>
<td class="label">NCT03799744</td>
<td>Umbilical cord OPCs</td>
</tr>
<tr>
<td class="label">NCT05030116</td>
<td>iPSC-derived OPCs</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">NCT05838438</td>
<td>OPC transplantation</td>
</tr>
<tr>
<td class="label">NCT04624217</td>
<td>OPC-secreted factors</td>
</tr>
</table>

...

Oligodendrocyte Precursor Cell Therapy

Overview

Oligodendrocyte precursor cell (OPC) therapy is a cell-based approach for treating demyelinating diseases and promoting remyelination in neurodegenerative conditions. OPCs are glial progenitor cells that differentiate into oligodendrocytes, the myelin-producing cells of the central nervous system (CNS). This therapy aims to transplant OPCs or stimulate endogenous OPCs to regenerate myelin sheaths damaged in conditions like multiple sclerosis (MS), Alzheimer's disease (AD), and Parkinson's disease (PD). [@zhang2006]

Pathway Diagram

Mermaid diagram (expand to render)

Knowledge graph relationships for Oligodendrocyte (612 total edges in KG)

Mechanism of Action

Oligodendrocyte Biology

Oligodendrocytes produce the myelin sheath that insulates axons, enabling rapid saltatory conduction. OPCs comprise approximately 5-10% of cells in the adult human brain and remain proliferative and responsive to demyelination. [@sim2011]

Myelin Repair Mechanisms

Direct Remyelination: Transplanted or endogenous OPCs differentiate into mature oligodendrocytes that wrap axons with new myelin.

Neurotrophic Support: OPCs secrete growth factors (NGF, BDNF, GDNF) that support neuron survival.

Immunomodulation: OPCs can modulate inflammatory responses in the CNS.

Axonal Support: Myelination provides metabolic support to axons through lactate shuttling.

OPC Dysfunction in Neurodegeneration

Multiple Sclerosis: OPCs fail to differentiate and remyelinate in chronic lesions
Alzheimer's Disease: White matter lesions and myelin breakdown contribute to cognitive decline
Parkinson's Disease: Myelin abnormalities in specific brain regions
Aging: OPC function declines with age, reducing repair capacity

Therapeutic Approaches

Cell Transplantation

Pharmacological Approaches

OPCs Activation: Agents that stimulate OPC proliferation/differentiation
Examples: Clemastine, miconazole, benztropine (approved for MS)
Mechanism: Block muscarinic receptors to promote differentiation

Gene Therapy

Delivery: AAV vectors encoding myelination factors
Targets: PDGF, SOX10, OLIG2 for enhanced OPC function

Clinical Evidence

Multiple Sclerosis (Primary Indication)

Alzheimer's Disease

Parkinson's Disease

Preclinical studies showing OPC-derived oligodendrocyte survival in dopaminergic regions
Myelin restoration may support axonal integrity in PD models

Preclinical Research

Animal Models

Cuprizone Model: Toxin-induced demyelination; OPC therapy promotes remyelination
EAE Model: MS-like disease; OPCs reduce inflammation and improve outcomes
AD Transgenic Mice: OPC transplantation reduced amyloid and improved cognition
PD Models: OPCs protected dopaminergic [neurons](/entities/neurons)

Key Findings

Human OPCs can successfully myelinate axons in rodent models
Functional recovery correlates with remyelination extent
Combination with neurotrophic factors enhances outcomes

Delivery Methods

Intrathecal Injection: Direct delivery to CSF; widely used

Intravenous Injection: Systemic; cells cross [BBB](/entities/blood-brain-barrier) in some cases

Stereotactic Injection: Direct to lesion sites

Intranasal: Non-invasive; targets CNS

Challenges and Limitations

Biological Challenges

OPC Aging: Aged OPCs have reduced differentiation capacity
Chronic Lesions: Glial scars inhibit OPC recruitment
Tumorigenicity: Risk with pluripotent cell-derived OPCs

Technical Challenges

Cell Survival: Low survival after transplantation
Functional Integration: Ensuring proper myelination
Manufacturing: Scalable production of clinical-grade OPCs

Regulatory Challenges

Complex cell therapy manufacturing requirements
Long-term safety monitoring needed
Standardized potency assays lacking

External Links

[PubMed: OPC Therapy Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=oligodendrocyte+precursor+cell+therapy+neurodegeneration)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[MS Society - Research Updates](https://mssociety.org.uk/research)

References

[Zhang et al., Human OPC transplantation in demyelinating disease (2006) (2006)](https://doi.org/10.1038/nm1410)

[Sim et al., Direct conversion of fibroblasts to OPCs (2011) (2011)](https://doi.org/10.1038/nature10579)

[Najm et al., Drug discovery for remyelination (2015) (2015)](https://doi.org/10.1038/nature19057)

[Cao et al., OPC therapy for AD in mouse models (2019) (2019)](https://doi.org/10.1038/s41582-019-0216-4)

[Unknown, Gallo & Deneen, Oligodendrogenesis (2014) (2014)](https://doi.org/10.1016/j.neuroscience.2014.03.050)

Unknown, NCT03269071 Clinical Trial (n.d.)

[Windrem et al., Neonatal human OPCs for myelination (2008) (2008)](https://doi.org/10.1038/nm.1928)

[Unknown, Bergles & Richardson, Oligodendrocyte precursor cells in disease (2015) (2015)](https://doi.org/10.1523/JNEUROSCI.3015-15.2015)

[Patani et al., OPC biology and therapy (2021) (2021)](https://doi.org/10.1016/j.tins.2021.08.005)

[Kremer et al., Remyelination strategies (2021) (2021)](https://doi.org/10.1038/s41582-021-00517-3)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Oligodendrocyte Precursor Cell Therapy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Oligodendrocyte Precursor Cell Therapy

Oligodendrocyte Precursor Cell Therapy

Overview

Oligodendrocyte Precursor Cell Therapy

Overview

Pathway Diagram

Mechanism of Action

Oligodendrocyte Biology

Myelin Repair Mechanisms

OPC Dysfunction in Neurodegeneration

Therapeutic Approaches

Cell Transplantation

Pharmacological Approaches

Gene Therapy

Clinical Evidence

Multiple Sclerosis (Primary Indication)

Alzheimer's Disease

Parkinson's Disease

Preclinical Research

Animal Models

Key Findings

Delivery Methods

Challenges and Limitations

Biological Challenges

Technical Challenges

Regulatory Challenges

See Also

External Links

References

Related Hypotheses

Pathway Diagram